Free tool
FAERS Monitor: Ruxience
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761103 or its brand name (Ruxience, Rituximab-Pvvr). Reports on generic versions are filed under their own applications.
Reports
5,245
Serious
4,747
91% of reports
Hospitalization
1,298
Death reported
494
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,152
- intentional product use issue643
- condition aggravated628
- fatigue409
- death394
- dyspnoea377
- covid-19361
- nausea358
- inappropriate schedule of product administration355
- pruritus347
- headache345
- throat irritation320
- malaise307
- pain302
- cough293
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 77 |
| 2021 | 397 |
| 2022 | 771 |
| 2023 | 1,153 |
| 2024 | 1,210 |
| 2025 | 1,092 |
| 2026 | 543 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,914 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intentional product use issueSignal | 643 | 29.6 | 27.6 | 17,712 |
| throat irritationSignal | 320 | 28.8 | 25.9 | 8,516 |
| off label useSignal | 2,152 | 9.9 | 9.6 | 17,862 |
| condition aggravatedSignal | 628 | 8.3 | 7.7 | 4,074 |
| covid-19Signal | 361 | 8.3 | 7.5 | 2,313 |
| inappropriate schedule of product administrationSignal | 355 | 7.9 | 7.2 | 2,151 |
| coughSignal | 293 | 4.2 | 3.8 | 718 |
| pruritusSignal | 347 | 3.6 | 3.3 | 668 |
| malaiseSignal | 307 | 2.8 | 2.5 | 363 |
| dyspnoeaSignal | 377 | 2.7 | 2.4 | 403 |
| headacheSignal | 345 | 2.2 | 2.0 | 233 |
| fatigueSignal | 409 | 2.1 | 1.9 | 246 |
| pain | 302 | 2.0 | 1.8 | 148 |
| death | 394 | 1.8 | 1.7 | 155 |
| nausea | 358 | 1.8 | 1.6 | 135 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.